trial

Long-Acting Injectable Risperidone in the Treatment of Schizophrenia

NCTId NCT00132314
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 382 (actual)
Sponsored by US Department of Veterans Affairs
Primary completion 2009-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
382 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-09
Primary completion
2009-09
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Risperidoneoral antipsychotic medication

Sponsors

US Department of Veterans AffairsLead Sponsor

Investigators

1
Robert A. Rosenheck, AB MDStudy Chair

Sites

19 total
Tuscaloosa, United StatesLong Beach, United StatesPalo Alto, United StatesWest Haven, United StatesMiami, United StatesAugusta, United StatesChicago, United StatesBoston, United StatesDetroit, United StatesMinneapolis, United StatesKansas City, United StatesOmaha, United States

Linked catalysts

1
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia — primary completion2009-09

Facts & assertions

4 sourced
Enrollment
382
Phase
PHASE3
Primary Completion Date
2009-09
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
oral antipsychotic medication
drug
lead_sponsor
US Department of Veterans Affairs
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Robert A. Rosenheck, AB MD
person